CAMP Valuation

CAMP4 Therapeutics Corp

Add to Watchlist

Advanced Chart

4.250

-0.2(-4.494%)1D

CAMP Relative Valuation

CAMP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CAMP is overvalued; if below, it's undervalued.

Historical Valuation

CAMP4 Therapeutics Corp (CAMP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 7.56. The fair price of CAMP4 Therapeutics Corp (CAMP) is between 11671.59 to 18176.77 according to relative valuation methord. Compared to the current price of 4.25 USD , CAMP4 Therapeutics Corp is Undervalued By 99.96%.

Relative Value

Fair Zone

11671.59-18176.77

Current Price：4.25

99.96%

Undervalued

0.04

Trailing

Forward

8.16

EV/EBITDA

CAMP4 Therapeutics Corp. (CAMP) has a current EV/EBITDA of 8.16. The 5-year average EV/EBITDA is 15.72. The thresholds are as follows: Strongly Undervalued below 5.96, Undervalued between 5.96 and 10.84, Fairly Valued between 20.60 and 10.84, Overvalued between 20.60 and 25.48, and Strongly Overvalued above 25.48. The current Forward EV/EBITDA of 8.16 falls within the Undervalued range.

47.19

EV/EBIT

CAMP4 Therapeutics Corp. (CAMP) has a current EV/EBIT of 47.19. The 5-year average EV/EBIT is 22.31. The thresholds are as follows: Strongly Undervalued below -98.06, Undervalued between -98.06 and -37.88, Fairly Valued between 82.49 and -37.88, Overvalued between 82.49 and 142.67, and Strongly Overvalued above 142.67. The current Forward EV/EBIT of 47.19 falls within the Historic Trend Line -Fairly Valued range.

0.00

CAMP4 Therapeutics Corp. (CAMP) has a current PS of 0.00. The 5-year average PS is 0.62. The thresholds are as follows: Strongly Undervalued below -0.34, Undervalued between -0.34 and 0.14, Fairly Valued between 1.10 and 0.14, Overvalued between 1.10 and 1.58, and Strongly Overvalued above 1.58. The current Forward PS of 0.00 falls within the Undervalued range.

0.00

P/OCF

CAMP4 Therapeutics Corp. (CAMP) has a current P/OCF of 0.00. The 5-year average P/OCF is 4.89. The thresholds are as follows: Strongly Undervalued below -10.41, Undervalued between -10.41 and -2.76, Fairly Valued between 12.54 and -2.76, Overvalued between 12.54 and 20.19, and Strongly Overvalued above 20.19. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

CAMP4 Therapeutics Corp. (CAMP) has a current P/FCF of 0.00. The 5-year average P/FCF is -6.52. The thresholds are as follows: Strongly Undervalued below -70.11, Undervalued between -70.11 and -38.32, Fairly Valued between 25.28 and -38.32, Overvalued between 25.28 and 57.08, and Strongly Overvalued above 57.08. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

CAMP4 Therapeutics Corp (CAMP) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 3.15 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 3.89, the current P/B ratio is about -100.00% higher. CAMP4 Therapeutics Corp (CAMP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -139.08%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -66.98% , the current FCF yield is about -100.00% lower.

0.00

P/B

Median3y

3.15

Median5y

3.89

0.00

FCF Yield

Median3y

-139.08

Median5y

-66.98

Competitors Valuation Multiple

The average P/S ratio for CAMP's competitors is 5.44, providing a benchmark for relative valuation. CAMP4 Therapeutics Corp Corp (CAMP) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -98.79%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CAMP.O

CAMP4 Therapeutics Corp

Rani Therapeutics Holdings Inc

2.27

245.45M

IPA.O

MindWalk Holdings Corp

Coeptis Therapeutics Holdings Inc

13.71

66.09M

Performance Decomposition

Market capitalization of CAMP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CAMP in the past 1 year is driven by Unknown.